Vaxcyte, Inc. (PCVX) Financials

PCVX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 3.3 billion 352.3 million
Dec. 31, 2025 3.0 billion 360.5 million
Sept. 30, 2025 3.2 billion 278.7 million
June 30, 2025 3.3 billion 234.0 million

PCVX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -295.4 million 38.0 million
Dec. 31, 2025 -219.3 million 36.0 million
Sept. 30, 2025 -155.4 million 35.3 million
June 30, 2025 -101.7 million 36.9 million

PCVX Net Income

No data available :(

PCVX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 1.7 billion - 110.2 million
Dec. 31, 2025 1.6 billion 111.4 million 111.4 million
Sept. 30, 2025 1.7 billion - 78.7 million
June 30, 2025 1.7 billion - 85.8 million

PCVX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 139.5 million
Dec. 31, 2025 136.1 million
Sept. 30, 2025 136.2 million
June 30, 2025 136.0 million

PCVX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 14.8 million 312.8 million 33.1 million -
Dec. 31, 2025 5.6 million 242.1 million 32.2 million -
Sept. 30, 2025 12.0 million 209.9 million 32.4 million -
June 30, 2025 19.5 million 194.2 million 32.0 million -

PCVX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 5.9 million
Dec. 31, 2025 - -5.0 million
Sept. 30, 2025 - -
June 30, 2025 - 5.0 million

PCVX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

PCVX

Price: $54.66

52 week price:
29.08
65.00

Earnings Per Share: -6.89 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 346400

Market Capitalization: 8.4 billion

Links: